JP2020516654A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516654A5
JP2020516654A5 JP2019555932A JP2019555932A JP2020516654A5 JP 2020516654 A5 JP2020516654 A5 JP 2020516654A5 JP 2019555932 A JP2019555932 A JP 2019555932A JP 2019555932 A JP2019555932 A JP 2019555932A JP 2020516654 A5 JP2020516654 A5 JP 2020516654A5
Authority
JP
Japan
Prior art keywords
composition
tumor
effector molecule
mesenchymal stem
produce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019555932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516654A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/027492 external-priority patent/WO2018191619A1/en
Publication of JP2020516654A publication Critical patent/JP2020516654A/ja
Publication of JP2020516654A5 publication Critical patent/JP2020516654A5/ja
Priority to JP2022147539A priority Critical patent/JP2022180471A/ja
Pending legal-status Critical Current

Links

JP2019555932A 2017-04-13 2018-04-13 組み合わせがん免疫療法 Pending JP2020516654A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022147539A JP2022180471A (ja) 2017-04-13 2022-09-16 組み合わせがん免疫療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762485295P 2017-04-13 2017-04-13
US62/485,295 2017-04-13
US201762583343P 2017-11-08 2017-11-08
US62/583,343 2017-11-08
PCT/US2018/027492 WO2018191619A1 (en) 2017-04-13 2018-04-13 Combinatorial cancer immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022147539A Division JP2022180471A (ja) 2017-04-13 2022-09-16 組み合わせがん免疫療法

Publications (2)

Publication Number Publication Date
JP2020516654A JP2020516654A (ja) 2020-06-11
JP2020516654A5 true JP2020516654A5 (enExample) 2021-05-06

Family

ID=62092349

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019555932A Pending JP2020516654A (ja) 2017-04-13 2018-04-13 組み合わせがん免疫療法
JP2022147539A Pending JP2022180471A (ja) 2017-04-13 2022-09-16 組み合わせがん免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022147539A Pending JP2022180471A (ja) 2017-04-13 2022-09-16 組み合わせがん免疫療法

Country Status (10)

Country Link
US (2) US11446332B2 (enExample)
EP (2) EP3610000A1 (enExample)
JP (2) JP2020516654A (enExample)
KR (1) KR20190141695A (enExample)
CN (2) CN110996975A (enExample)
AU (1) AU2018251898A1 (enExample)
CA (1) CA3059634A1 (enExample)
IL (1) IL269810A (enExample)
SG (1) SG10202111394XA (enExample)
WO (1) WO2018191619A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7305300B2 (ja) * 2014-11-05 2023-07-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 併用免疫療法
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
JP7340591B2 (ja) 2018-07-11 2023-09-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
CA3132184A1 (en) 2019-04-04 2020-10-08 Mark Lewis Molded article made by a pulp composition providing grease and water-resistant properties
US20220280609A1 (en) * 2019-07-17 2022-09-08 The Regents Of The University Of California Combination cancer therapy agents and methods
US20220378822A1 (en) * 2019-08-28 2022-12-01 Senti Bioscience, Inc. Combinatorial cancer immunotherapy
WO2021055731A1 (en) * 2019-09-20 2021-03-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Il-36 cytokine expressing oncolytic viruses for treating cancer
IL292836A (en) * 2019-11-12 2022-07-01 Actym Therapeutics Inc Platforms for administering bacteria that stimulate the immune system and their use for administering therapeutic products
CN112980886B (zh) * 2019-12-02 2022-02-22 河北森朗生物科技有限公司 一种能高效制备且应用安全的嵌合抗原受体t细胞及其制备方法与应用
JP7758370B2 (ja) * 2020-07-16 2025-10-22 チャンジェン セラピューティクス (シャンハイ) カンパニー リミテッド 間葉系幹細胞によるケモカインおよびサイトカイン送達を標的とする免疫療法
CN114276995A (zh) * 2020-09-28 2022-04-05 未来智人再生医学研究院(广州)有限公司 一种表达ctla-4阻遏分子的多能干细胞及其衍生物
CN114350612A (zh) * 2020-09-28 2022-04-15 未来智人再生医学研究院(广州)有限公司 表达靶向CTLA-4的shRNA/shRNA-miR的多能干细胞或其衍生物
CN114426953A (zh) * 2020-10-29 2022-05-03 未来智人再生医学研究院(广州)有限公司 一种表达il-12的多能干细胞衍生物及应用
CN114507643A (zh) * 2020-10-29 2022-05-17 未来智人再生医学研究院(广州)有限公司 一种表达il-2的多能干细胞衍生物及应用
CN114457023A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达cd28激活型抗体的多能干细胞及其衍生物与应用
CN114457022A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用
CN114457024A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IL-4Rα阻断物的多能干细胞或其衍生物及应用
CN114525255A (zh) * 2020-10-30 2022-05-24 未来智人再生医学研究院(广州)有限公司 一种表达il-11的多能干细胞衍生物及其应用
CN114457026A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
CN114457029A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达vegf-a阻断物的多能干细胞或其衍生物及应用
CN114457030A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达IgE阻断物的多能干细胞或其衍生物及应用
CN114645021A (zh) * 2020-12-21 2022-06-21 未来智人再生医学研究院(广州)有限公司 一种表达靶向cd47抑制因子的多能干细胞及其衍生物与应用
CN114717232A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 表达irf-1靶向抑制因子的多能干细胞及其衍生物与应用
CN114657138A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向B7-H4的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN114657134A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达靶向IgE的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN114717192A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 一种表达Amyloidβ靶向抑制因子的多能干细胞及其衍生物与应用
CN114657130A (zh) * 2020-12-22 2022-06-24 未来智人再生医学研究院(广州)有限公司 一种表达vegf-a靶向抑制因子的多能干细胞及其衍生物与应用
CN114717193A (zh) * 2020-12-22 2022-07-08 未来智人再生医学研究院(广州)有限公司 一种表达靶向B7-H5的shRNA和/或shRNA-miR的多能干细胞或其衍生物
CN115433734B (zh) * 2022-06-01 2025-03-04 北京奇糖科技有限公司 核酸片段及其在制备肿瘤疫苗中的应用

Family Cites Families (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5328988A (en) 1987-10-26 1994-07-12 Immunex Corporation Interleukin-7
US5714585A (en) 1987-10-26 1998-02-03 Sterling Winthrop, Inc. Antibodies that are immunoreactive with interleukin-7
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5674486A (en) 1991-06-25 1997-10-07 San Diego Regional Cancer Center Cancer immunotherapy with carrier cells
US5981724A (en) 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
AU4543193A (en) 1992-06-22 1994-01-24 Henry E. Young Scar inhibitory factor and use thereof
US7537932B1 (en) 1993-05-19 2009-05-26 Schering Corporation Antibodies that bind purified mammalian FLT3 ligands
NZ314644A (en) 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5536657A (en) 1993-07-19 1996-07-16 Hoffmann-La Roche Inc. Recombinant DNA encoding human receptor for interleukin-12
US5591625A (en) 1993-11-24 1997-01-07 Case Western Reserve University Transduced mesenchymal stem cells
NZ266264A (en) 1994-04-06 1997-01-29 Immunex Corp Mammalian epithelium-derived t-cell factor called interleukin-15
US5780268A (en) 1995-12-06 1998-07-14 Incyte Pharmaceuticals Chemokine expressed in a mixed lymphocyte reaction
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
CA2269074A1 (en) 1996-10-23 1998-04-30 The Trustees Of The University Of Pennsylvania Immunotherapy and improved vaccines
JP2001522226A (ja) 1997-01-31 2001-11-13 リサーチ コーポレイション テクノロジーズ インコーポレイテッド セミ−同種異系細胞での癌の免疫療法
US8034332B2 (en) * 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
US6153182A (en) 1997-12-19 2000-11-28 Uab Research Foundation Lymphotactin as an adjuvant
US20010023070A1 (en) 1998-05-29 2001-09-20 Reinhard Ebner Interleukins-21 and 22
EP1082433A4 (en) 1998-05-29 2003-01-02 Human Genome Sciences Inc Interleukins 21 and 22
DE19833476B4 (de) 1998-07-24 2005-08-25 Huss, Ralf, Dr. Genetisch modifizierte CD34-Negative, adhärent wachsende hämatopoetische Stammzellen und deren Verwendung in der Gentherapie
US6392126B1 (en) 1999-02-25 2002-05-21 Pioneer Hi-Bred International, Inc. Adenosine deaminase homologues and uses thereof
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
DE60233888D1 (de) 2001-11-05 2009-11-12 Zymogenetics Inc Il-21-antagonisten
EP1487463A2 (en) * 2002-03-02 2004-12-22 Board Of Regents The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
US20050063947A1 (en) 2002-03-27 2005-03-24 Patrick Hwu Method for treating cancer in humans
AU2003273574A1 (en) 2002-05-31 2003-12-19 Osiris Therapeutics, Inc. Intraperitoneal delivery of genetically engineered mesenchymal stem cells
AU2003287429A1 (en) * 2002-11-01 2004-06-07 Five Prime Therapeutics, Inc. Stem cell libraries
EP1641915B1 (en) 2003-06-27 2016-07-27 DePuy Synthes Products, Inc. Repair and regeneration of ocular tissue using postpartum-derived cells
JPWO2005007176A1 (ja) 2003-06-27 2006-08-31 株式会社レノメディクス研究所 間葉系細胞を有効成分とする体内投与用脳神経疾患治療薬
US7052772B2 (en) 2003-08-14 2006-05-30 3M Innovative Properties Company Material for packaging electronic components
US20050037306A1 (en) 2003-08-16 2005-02-17 Tetsuo Nakatsu Candle system for enhancing burning and improving volatiles performance and a manufacturing method for the same
WO2005037218A2 (en) 2003-10-17 2005-04-28 Actis Biologics, Inc. Lentiviral vector delivery of il-21 for treatment of cancer
EP1680138B1 (en) 2003-10-17 2013-07-17 Novo Nordisk A/S Combination therapy
GB0400031D0 (en) 2004-01-03 2004-02-04 Univ Sheffield Depression treatment
EP1778298A4 (en) 2004-04-01 2010-03-31 Univ Pennsylvania LIPOPROTEIN-NANO PLATFORMS
DE602005016683D1 (de) * 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
CA2580336C (en) 2004-07-22 2016-07-19 Roger Kingdon Craig Vh heavy chain only antibodies, and vh heavy chain only dimer compounds and uses thereof
DE102005057426A1 (de) 2005-11-30 2007-05-31 Andritz Küsters GmbH & Co. KG Unterdruck-Bandfördervorrichtung zum Führen einer laufenden Bahn
WO2007084364A2 (en) 2006-01-13 2007-07-26 The Government Of The United States, As Represented By The Secretary Of Health And Human Services, National Institutes Of Health Improved il-12 for expression in mammalian cells
DK1976871T3 (da) 2006-01-13 2011-12-12 Univ Pennsylvania Vacciner og immunterapeutika under anvendelse af codonoptimerede IL-15 og fremgangsmåder til anvendelse deraf
US9303080B2 (en) 2006-01-13 2016-04-05 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized IL-15 and IL-15R-alpha genes for expression in mammalian cells
KR100788930B1 (ko) 2006-04-18 2007-12-27 포항공과대학교 산학협력단 항암 조성물
CA2655990A1 (en) 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
US8304931B2 (en) 2006-12-18 2012-11-06 Decicon, Inc. Configurable power supply integrated circuit
EP2856876B1 (en) * 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
TWI486169B (zh) 2007-04-20 2015-06-01 Sigma Tau Rare Diseases S A 酵素性抗癌療法
PL2147116T3 (pl) 2007-04-20 2016-08-31 Leadiant Biosciences Ltd Stabilna rekombinowana dezaminaza adenozynowa
US20110038836A1 (en) * 2007-04-23 2011-02-17 The Board Of Regents, The University Of Texas System Device and Method for Transfecting Cells for Therapeutic Use
CA2723320C (en) 2007-05-04 2019-06-11 University Health Network Il-12 immunotherapy for cancer
PL2162534T3 (pl) 2007-05-24 2015-02-27 Apceth Gmbh & Co Kg Genetycznie zmodyfikowane, mezenchymalne komórki macierzyste CD34 negatywne do leczenia nowotworów
EP2034025A1 (en) 2007-09-04 2009-03-11 Freie Universität Berlin Inflammation-induced anti-inflammatory gene expression
US20110020242A1 (en) 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
US8557872B2 (en) 2008-01-28 2013-10-15 Amorepacific Corporation Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
BRPI0920679A2 (pt) 2008-10-08 2022-05-17 Intrexon Corp Células construídas expressando múltiplos imunomoduladores e usos das mesmas
ES2749500T3 (es) 2008-11-19 2020-03-20 Celularity Inc Células adherentes derivadas del amnios
EP2419113B1 (en) 2009-04-13 2017-05-10 Apceth GmbH & Co. KG Engineered mesenchymal stem cells and method of using same to treat tumors
WO2010128636A1 (ja) 2009-05-08 2010-11-11 日本電気株式会社 通信システム、通信装置、通信方法及びプログラム
WO2011114919A1 (en) 2010-03-19 2011-09-22 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device
EP2614151B1 (en) 2010-09-08 2019-07-24 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Interleukin 15 as selectable marker for gene transfer in lymphocytes
US20140017787A1 (en) 2010-10-11 2014-01-16 Aline M. Betancourt Mesenchymal stem cells and related therapies
ES2649967T3 (es) 2011-04-08 2018-01-16 Baylor College Of Medicine Inversión de los efectos del microentorno tumoral utilizando receptores quiméricos de citocinas
US20140255363A1 (en) 2011-09-16 2014-09-11 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EP2872619B1 (en) 2012-07-11 2018-02-14 Imstem Biotechnology Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
CA2876499C (en) 2012-07-12 2021-10-26 Imstem Biotechnology, Inc. Mesenchymal-like stem cells derived from human embryonic stem cells, methods and uses thereof
BR112015031729A2 (pt) 2013-06-19 2017-07-25 Univ Miami sistema de classificação, métodos e kit para classificação, prognóstico e tratamento de câncer de mama
EP3021853A1 (en) * 2013-07-18 2016-05-25 Baylor College Of Medicine Method of enhancing potency of immune cells
JP2015030819A (ja) 2013-08-05 2015-02-16 株式会社ジェイテクト アクリルゴム組成物およびこれを備えたシール装置
AR097570A1 (es) 2013-09-06 2016-03-23 Consejo Nac De Investig Científicas Y Técnicas (Conicet) Composiciones y métodos para incrementar la migración de células mesenquimales del estroma hacia tumores
EA201691607A1 (ru) 2014-02-11 2017-01-30 Антродженезис Корпорейшн Микроорганоиды и способы их получения и применения
JP6468712B2 (ja) 2014-03-28 2019-02-13 大和ハウス工業株式会社 通信ユニット
KR101723786B1 (ko) 2014-03-28 2017-04-06 가톨릭대학교 산학협력단 Il―21을 발현하는 중간엽 줄기세포를 포함하는 b 세포 림프종 예방 또는 치료용 조성물
KR20160011916A (ko) 2014-07-23 2016-02-02 삼성전자주식회사 얼굴 인식을 통한 사용자 식별 방법 및 장치
EP3660042B1 (en) 2014-07-31 2023-01-11 Novartis AG Subset-optimized chimeric antigen receptor-containing t-cells
US9730938B2 (en) 2014-08-08 2017-08-15 Pharmacyclics Llc Bruton's tyrosine kinase inhibitor combinations and uses thereof
US9918718B2 (en) 2014-08-08 2018-03-20 DePuy Synthes Products, Inc. Embolic coil delivery system with retractable mechanical release mechanism
EP3182984B1 (en) * 2014-08-18 2019-10-30 Apceth GmbH & Co. KG Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
WO2016103071A1 (en) 2014-12-23 2016-06-30 Husqvarna Ab Lawn monitoring and maintenance via a robotic vehicle
KR20160089688A (ko) 2015-01-20 2016-07-28 삼성전자주식회사 엑스선 영상 장치, 및 그 제어방법
US20160237407A1 (en) 2015-02-17 2016-08-18 Batu Biologics, Inc. Universal donor chimeric antigen receptor cells
WO2016146819A1 (en) 2015-03-18 2016-09-22 Apceth Gmbh & Co. Kg Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells
WO2016191283A2 (en) 2015-05-22 2016-12-01 University Of Houston System Enzymatic immunomodulation of solid tumors and user thereof
EP4424326A3 (en) * 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
US10617406B2 (en) 2015-06-30 2020-04-14 Smith & Nephew, Inc. Suture anchor system with threaded plug
EP4043556B1 (en) * 2015-06-30 2024-02-07 Cellectis Methods for improving functionality in nk cell by gene inactivation using specific endonuclease
WO2017001630A1 (en) 2015-06-30 2017-01-05 British Telecommunications Public Limited Company Model management in a dynamic qos environment
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
CA2997912A1 (en) * 2015-09-09 2017-03-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Genetic engineering of macrophages for immunotherapy
CN105206757B (zh) 2015-11-05 2016-09-07 京东方科技集团股份有限公司 有机发光二极管及其制作方法、显示基板和显示装置
US10008344B2 (en) 2015-11-11 2018-06-26 Htc Corporation Switch assembly and hand-held device
US10533157B1 (en) * 2015-12-03 2020-01-14 Nantbio, Inc. Recombinant NK cells expressing co-stimulatory molecules
WO2017133175A1 (en) 2016-02-04 2017-08-10 Nanjing Legend Biotech Co., Ltd. Engineered mammalian cells for cancer therapy
US20210205370A1 (en) 2016-02-18 2021-07-08 Pluristem Ltd. Methods and compositions for treating cancers and neoplasms
KR101833971B1 (ko) 2016-02-19 2018-03-02 사회복지법인 삼성생명공익재단 중간엽 줄기세포 또는 xcl1을 포함하는 근육질환의 예방 또는 치료용 약학적 조성물
JP7080819B2 (ja) 2016-02-25 2022-06-06 セル メディカ スイッツァランド アーゲー Pd-l1に対する結合メンバー
EP3462883B1 (en) 2016-06-07 2023-08-16 The Pacific Heart, Lung,&Blood Institute Compositions and their use in treating cancer
JP7114490B2 (ja) 2016-06-24 2022-08-08 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体(CARs)の構成およびその使用方法
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
US11529393B2 (en) 2016-10-10 2022-12-20 The Board Of Trustees Of The Leland Stanford Junior University Mesenchymal stem cells expressing anti-inflammatory cytokines and methods of use
JP6607179B2 (ja) 2016-12-15 2019-11-20 トヨタ自動車株式会社 車両の制御装置
WO2018161038A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il12 compositions and methods for immunotherapy
WO2018161026A1 (en) 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
EP3589373A4 (en) 2017-03-03 2020-12-23 Obsidian Therapeutics, Inc. COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY
US20200085876A1 (en) 2017-03-17 2020-03-19 Senti Biosciences, Inc. Immunomodulating cell circuits
AU2018251898A1 (en) 2017-04-13 2019-10-31 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CA3063723A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
AU2019359890B2 (en) 2018-10-17 2024-10-24 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN115851605A (zh) * 2019-04-18 2023-03-28 上海交通大学 间充质干细胞靶向运输趋化因子和细胞因子的免疫疗法
US20220378822A1 (en) * 2019-08-28 2022-12-01 Senti Bioscience, Inc. Combinatorial cancer immunotherapy

Similar Documents

Publication Publication Date Title
JP2020516654A5 (enExample)
Hack et al. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: challenges and opportunities
Takahashi et al. Immunosuppressive activity of cancer-associated fibroblasts in head and neck squamous cell carcinoma
Zhang et al. Yin-yang effect of tumor infiltrating B cells in breast cancer: From mechanism to immunotherapy
PH12021552300A1 (en) EGFR x CD28 MULTISPECIFIC ANTIBODIES
Joseph et al. Pre-treatment lymphocytopaenia is an adverse prognostic biomarker in muscle-invasive and advanced bladder cancer
JP2020103301A5 (enExample)
AU2013327116B2 (en) Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
Atreya et al. Systemic therapy for metastatic colorectal cancer: from current standards to future molecular targeted approaches
AU2018251898A1 (en) Combinatorial cancer immunotherapy
JP2019519499A5 (enExample)
JP2016528195A5 (enExample)
JP2018517415A5 (enExample)
JP2015506961A5 (enExample)
Jacobsohn et al. Adjuvant therapy for renal cell carcinoma
PH12020551187A1 (en) Bispecific antigen-binding molecules and methods of use
Ouladan et al. Chimeric antigen receptor-t cells in colorectal cancer: pioneering new avenues in solid tumor immunotherapy
Mauro et al. Effects of locoregional radiotherapy in patients with metastatic breast cancer
He et al. TNFR2-expressing CD4+ Foxp3+ regulatory T cells in cancer immunology and immunotherapy
Kronig et al. Hurdles race for CAR T‐cell therapy in digestive tract cancer
Russell Personalized medicine for breast cancer: it is a new day!
MX2022013920A (es) Anticuerpos anti-antigeno asociado con tumor y usos de los mismos.
EA201991870A1 (ru) Лечение рака мочевого пузыря с помощью антитела к pd-l1
Pan et al. Targeting breast cancer stem cells directly to treat refractory breast cancer
MX2023009211A (es) Anticuerpos biespecificos con pares de carga y usos de los mismos.